[HTML][HTML] Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
A Soosainathan, M Iravani, R El-Botty, J Alexander… - Cancer Research, 2024 - AACR
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine-and Palbociclib-Resistant ER+ Breast Cancers
A Soosainathan, M Iravani, R El-Botty… - Cancer …, 2024 - pubmed.ncbi.nlm.nih.gov
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an
effective and well-tolerated treatment for estrogen receptor-positive (ER+) breast cancer, yet …
effective and well-tolerated treatment for estrogen receptor-positive (ER+) breast cancer, yet …
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
A Soosainathan, M Iravani, R El-Botty, J Alexander… - Cancer Research, 2024 - AACR
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine-and Palbociclib-Resistant ER+ Breast Cancers.
A Soosainathan, M Iravani, R El-Botty… - Cancer …, 2024 - repository.icr.ac.uk
UNLABELLED: The combination of endocrine therapy and CDK4/6 inhibitors such as
palbociclib is an effective and well-tolerated treatment for estrogen receptor-positive (ER+) …
palbociclib is an effective and well-tolerated treatment for estrogen receptor-positive (ER+) …
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine-and Palbociclib-Resistant ER+ Breast Cancers.
A Soosainathan, M Iravani, R El-Botty… - Cancer …, 2024 - europepmc.org
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
[HTML][HTML] Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine-and Palbociclib-Resistant ER+ Breast Cancers
A Soosainathan, M Iravani, R El-Botty… - Cancer …, 2024 - ncbi.nlm.nih.gov
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
effective and well-tolerated treatment for estrogen receptor–positive (ER+) breast cancer, yet …
Targeting transcriptional regulation with a CDK9 inhibitor suppresses growth of endocrine-and palbociclib-resistant ER+ breast cancers.
A Soosainathan, M Iravani, R El-Botty… - Cancer …, 2023 - europepmc.org
The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an
effective and well-tolerated treatment for estrogen receptor positive (ER+) breast cancer, yet …
effective and well-tolerated treatment for estrogen receptor positive (ER+) breast cancer, yet …